DevCo's lexipafant renaissance

Nearly a year to the day that British Biotech plc announced that it was dropping Zacutex lexipafant as a potential treatment for acute pancreatitis, DevCo Pharmaceuticals Ltd. announced plans to resurrect the platelet activating factor antagonist for the prophylaxis of neurological and renal complications

Read the full 443 word article

How to gain access

Continue reading with a
two-week free trial.